A NEW SKYLINE FOR EPIGENETIC TREATMENT

Main Article Content

Pramod Khatri

Abstract

Histone lysine demethylases are chromatin modifiers which play important roles in numerous pathological
procedures for example inflammation and tumor, making them possibly alluring drug targets. In a latest study,
Kruidenier et al. gave verification of concept by recognizing chemical matters that hinder demethylation
interceded by the two identified histone H3 lysine 27 demethylases, KDM6A and 6B (UTX and JMJD3). The KDM6
inhibitor shows amazing substrate selectivity and can hinder transcription of a plenty of pro-inflammatory genes
in cell culture by modifying H3K27me3 level at a portion of the KDM6 target genes.
KEY WORDS: KDM6A, H3K27

Article Details

How to Cite
Khatri, P. (2016). A NEW SKYLINE FOR EPIGENETIC TREATMENT. International Journal of Pharmaceutical and Biological Science Archive, 1(1). Retrieved from http://ijpba.in/index.php/ijpba/article/view/3
Section
Short Communications